+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis

Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis

Faseb Journal 20(13): 2384-2386

Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term transgene expression. Its potential utility in treating organ transplantation-associated long-term complications has not yet been explored. In the present study we generated an improved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that possesses both T cell-suppressive and antioxidant properties and selectively delivered the SB transposon in combination with a hyperactive transposase plasmid to donor lung using the cationic polymer polyethylenimine (PEI) as transfection reagent. This nonviral gene therapeutic approach led to persistent and uniform transgene expression in the rat lung tissue without noticeable toxicity and inflammation. Importantly, IDO activity produced by hIDO transgene showed a remarkable therapeutic response, as evident by near normal pulmonary function ( peak airway pressure and oxygenation), histological appearance, and reduced collagen content in lung allografts. In addition, we established a hIDO-overexpressing type II cell line using the SB-based gene transfer system and found that hIDO-overexpressing lung cells effectively inhibited transforming growth factor-beta-stimulated fibroblast proliferation in vitro. In summary, the SB-based gene therapy with hIDO represents a new strategy for treating lung transplantation-associated chronic complications, e.g., obliterative bronchiolitis.

(PDF emailed within 0-6 h: $19.90)

Accession: 033411473

Download citation: RISBibTeXText

PMID: 17015408

DOI: 10.1096/fj.06-6228fje

Related references

Co-delivery of sleeping beauty transposons encoding FVIII and indoleamine 2,3-dioxygenase attenuate inhibitor formation resulting in long-term FVIII expression. 2007

Indoleamine 2,3-dioxygenase in lung allograft tolerance. Journal of Heart and Lung Transplantation 28(11): 1185-1192, 2010

Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. American Journal of Respiratory and Critical Care Medicine 173(5): 566-572, 2005

Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. American Journal of Physiology. Heart and Circulatory Physiology 293(6): H3415-H3423, 2007

Induction of indoleamine 2,3-dioxygenase by gene delivery in allogeneic islets prolongs allograft survival. American Journal of Transplantation 10(8): 1918-1924, 2010

Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft. International Immunopharmacology 36(): 31-38, 2016

Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. Journal of Gene Medicine 10(7): 754-761, 2008

Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. European Journal of Immunology 36(3): 690-700, 2006

Effects Of Indoleamine 2, 3-Dioxygenase Gene Modified Bone Marrow Mesenchymal Stem Cells In Rat Composite Tissue Allograft Rejection. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 28(6): 745-751, 2016

Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation. Oncotarget 8(25): 40486-40500, 2017

Indoleamine 2,3-dioxygenase 1 is a lung-specific innate immune defense mechanism that inhibits growth of Francisella tularensis tryptophan auxotrophs. Infection and Immunity 78(6): 2723-2733, 2010

Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth. Oncotarget 7(22): 32329-32340, 2016

Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. International Journal of Oncology 40(4): 929-934, 2012

IL-32 induces indoleamine 2,3-dioxygenase + CD1c + dendritic cells and indoleamine 2,3-dioxygenase + CD163 + macrophages: Relevance to mycosis fungoides progression. Oncoimmunology 6(2): E1181237-E1181237, 2017

Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. International Immunology 26(12): 673-684, 2015